MRUS
Merus N.V. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.66M | n/a | $98.40M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 2 | T. Rowe Price ✦ | 1.39M | n/a | $81.96M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Marshall Wace ✦ | 957.95K | n/a | $56.68M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 4 | Adage Capital Partners ✦ | 770.00K | n/a | $45.56M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 633.23K | n/a | $37.47M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 521.34K | n/a | $30.85M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 243.26K | n/a | $14.39M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 181.85K | n/a | $10.76M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Geode Capital Management ✦ (passive) | 52.19K | n/a | $3.09M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 8.47K | n/a | $501,170 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.